Grant of Licence

RNS Number:9627G
Henderson Morley PLC
31 July 2006

FOR IMMEDIATE RELEASE                                               31 JULY 2006



                              HENDERSON MORLEY PLC
                                     (AIM)

                        Business: Drug Discovery Company


                HENDERSON MORLEY GRANTS LICENCE TO AMISTAD PHARMA

The Board of Henderson Morley plc, ("Henderson Morley" or "the Company") the 
AIM listed drug discovery company, is pleased to announce that it has granted a 
licence in respect of Ionic Contra Viral Therapy ("ICVT") to AMISTAD PHARMA, 
a company whose focus is mainly on women's health care.

Key Points:

*The Licence has been granted to Amistad Pharma - an independent French
 pharmaceutical company specialising in women's healthcare;

*This will be an exclusive worldwide licence to bring products to
 market through a programme of pre-clinical and clinical development;

*Amistad will pay Henderson Morley 40% of all Net Receipts
 received in respect of sub-licences;

*Henderson Morley will receive a royalty equal to 10% of
 AMISTAD sales.

The Licence has been granted to Amistad Pharma SAS, an independent French 
pharmaceutical company specialising in women's healthcare.

Chairman of Amistad is Dr Alain Munoz. Dr. Alain Munoz was formerly VP of R & D 
and Business Development for the French pharmaceutical company, Fournier. He is
also a former member of the scientific committee of the French Drug Agency 
(Agence du Medicament). He has an in-depth knowledge of the US and Japanese
markets, and has concluded several major licensing deals with world-class 
partners in the industry.

The License Agreement is for a new application of ICVT for the topical treatment 
of genital and labial herpes and certain other dysplasias.  The licence will be 
an exclusive worldwide licence to bring the products to market through a 
programme of pre-clinical and clinical development of the treatment either by 
Amistad or through a sub-licence.

Amistad is obliged to conduct and complete certain pre-clinical and 
pre-development milestones including formulation, at its cost, within a period 
of 18 months from the date that is 45 days after 27 July 2006.

Amistad shall pay Henderson Morley 40% of all Net Receipts received by Amistad
or its Associates where "Net Receipts" means all royalties, licence fees,
development milestone payments and other comparable fees or other valuable
consideration received by Amistad or its Associates from its Sub-Licensees in
respect of the sub-licence of the Henderson Morley Technology.

Amistad shall pay to Henderson Morley a royalty 10% of the aggregate Net Sales
of all Licensed Products sold by or for the account of Amistad or its
Associates.

Amistad will be expected to:

*develop at least one commercially viable Licensed Product;

*obtain or cause to be obtained Product Approvals for at least one Licensed 
 Product; and

*commercially launch at least one Licensed Product in each country where 
 Product Approval has been granted

Commenting on the Agreement, Executive Chairman Andrew Knight said: "We are very
pleased to have signed this licence with Amistad. Dr Munoz is a well respected
figure in the pharmaceutical industry and we look forward to working with him
and his team to bring the ICVT products to market."

Dr Alain Munoz, Chairman of Amistad also commented: "The ICVT technology will
fit very well with the Amistad proprietary technology and I am delighted that,
together with Henderson Morley, we will develop an innovative product in an area
where there is an unsatisfied medical need."


                                    --ENDS--


Enquiries:

HENDERSON MORLEY PLC                                          Tel: 0121 442 4600
Andrew Knight, Chairman

BREWIN DOLPHIN SECURITIES LTD                                 Tel: 0113 241 0126
Neil Baldwin

BISHOPSGATE COMMUNICATIONS LTD                                Tel: 020 7430 1600
Maxine Barnes                                               Mobile: 07860 489571
Scott Robertson




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
STRGCGDRDDXGGLB
Henderson Mrly. (LSE:HML)
過去株価チャート
から 6 2024 まで 7 2024